In January of this year, the AIDS Crisis Task Force (Task Force) and AbbVie reached a landmark pricing agreement that offers their new Hepatitis C (HCV) treatment regimen, Viekira Pak, at a significantly lower cost for state and territory AIDS Drugs Assistance Programs (ADAPs). For last month’s research question for the HIV/HCV Co-Infection Watch Report, I asked every ADAP Director and Coordinator if this pricing agreement had caused their individual states to consider adding the regimen to their respective formularies. Read more: communityaccessnationalnetw...